The 2 most recent market catalysts affecting $EIKN, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Maintains Underperform on Eikon Therapeutics, Lowers Price Target to $4
Wedbush analyst Robert Driscoll maintained an 'Underperform' rating for Eikon Therapeutics and lowered the price target from $5 to $4. This action signals a continued lack of confi…
Aug 11, 2026
Corporate Catalyst
Neutral
Impact 65
Eikon Therapeutics Announces Selection Of Dose Of 0.60 mg/m2 To Be Employed In Future For All Patients Randomized To Receive EIK1001 In TeLuRide-006 Trial
Eikon Therapeutics announced the selection of a 0.60 mg/m2 dose for its EIK1001 drug in the TeLuRide-006 clinical trial, based on a recommendation from an independent Data Monitori…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.